Alnylam Pharmaceuticals
ALNY
#580
Rank
A$61.07 B
Marketcap
A$460.48
Share price
-2.08%
Change (1 day)
17.62%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -A$0.34 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$3.21 Billion. In 2024 the company made an earning of -A$0.34 Billion, an increase over its 2023 earnings that were of -A$0.45 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-A$0.34 Billion-24.59%
2023-A$0.45 Billion-67.84%
2022-A$1.38 Billion36.93%
2021-A$1.01 Billion-8.04%
2020-A$1.09 Billion-15.66%
2019-A$1.3 Billion12.23%
2018-A$1.16 Billion62.91%
2017-A$0.71 Billion17.78%
2016-A$0.6 Billion43.44%
2015-A$0.42 Billion60.69%
2014-A$0.27 Billion98.2%
2013-A$0.14 Billion
2011-A$77.44 Million27.48%
2010-A$60.74 Million-10.92%
2009-A$68.19 Million95.77%
2008-A$34.83 Million
2006-A$55.8 Million-9.13%
2005-A$61.41 Million34.74%
2004-A$45.58 Million36.79%
2003-A$33.32 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$23.09 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$12.85 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$7.38 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.36 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$67 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.23 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$3.03 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.19 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA